MBA Advisors LLC Buys 516 Shares of Johnson & Johnson $JNJ

MBA Advisors LLC boosted its stake in shares of Johnson & Johnson (NYSE:JNJ) by 9.3% in the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 6,069 shares of the company’s stock after buying an additional 516 shares during the quarter. MBA Advisors LLC’s holdings in Johnson & Johnson were worth $927,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in JNJ. Brighton Jones LLC lifted its holdings in Johnson & Johnson by 13.9% during the 4th quarter. Brighton Jones LLC now owns 51,876 shares of the company’s stock valued at $7,502,000 after buying an additional 6,332 shares in the last quarter. HBW Advisory Services LLC increased its position in Johnson & Johnson by 13.3% during the 1st quarter. HBW Advisory Services LLC now owns 7,401 shares of the company’s stock valued at $1,227,000 after purchasing an additional 867 shares during the period. RFG Advisory LLC increased its position in Johnson & Johnson by 9.0% during the 1st quarter. RFG Advisory LLC now owns 18,278 shares of the company’s stock valued at $3,031,000 after purchasing an additional 1,515 shares during the period. Whipplewood Advisors LLC increased its position in Johnson & Johnson by 5.3% during the 1st quarter. Whipplewood Advisors LLC now owns 1,636 shares of the company’s stock valued at $295,000 after purchasing an additional 82 shares during the period. Finally, Apella Capital LLC increased its position in Johnson & Johnson by 13.6% during the 1st quarter. Apella Capital LLC now owns 27,649 shares of the company’s stock valued at $4,174,000 after purchasing an additional 3,314 shares during the period. Institutional investors own 69.55% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research analysts have commented on the stock. Citigroup raised their target price on shares of Johnson & Johnson from $185.00 to $200.00 and gave the company a “buy” rating in a research report on Thursday, August 21st. Barclays raised their target price on shares of Johnson & Johnson from $165.00 to $176.00 and gave the company an “equal weight” rating in a research report on Thursday, July 17th. The Goldman Sachs Group raised their target price on shares of Johnson & Johnson from $185.00 to $186.00 and gave the company a “buy” rating in a research report on Friday, September 19th. Morgan Stanley lifted their price objective on shares of Johnson & Johnson from $171.00 to $176.00 and gave the stock an “equal weight” rating in a research report on Thursday, July 17th. Finally, UBS Group lifted their price objective on shares of Johnson & Johnson from $180.00 to $190.00 and gave the stock a “buy” rating in a research report on Thursday, July 17th. Two investment analysts have rated the stock with a Strong Buy rating, ten have assigned a Buy rating and nine have issued a Hold rating to the company. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $181.40.

Insiders Place Their Bets

In other Johnson & Johnson news, EVP Jennifer L. Taubert sold 56,471 shares of the business’s stock in a transaction that occurred on Thursday, September 4th. The shares were sold at an average price of $177.81, for a total transaction of $10,041,108.51. Following the sale, the executive vice president owned 178,013 shares of the company’s stock, valued at approximately $31,652,491.53. The trade was a 24.08% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Corporate insiders own 0.16% of the company’s stock.

Johnson & Johnson Stock Up 0.3%

Shares of Johnson & Johnson stock opened at $185.99 on Thursday. The firm’s 50 day moving average price is $175.45 and its 200-day moving average price is $162.51. The company has a quick ratio of 0.76, a current ratio of 1.01 and a debt-to-equity ratio of 0.50. Johnson & Johnson has a 52-week low of $140.68 and a 52-week high of $186.56. The company has a market cap of $447.92 billion, a P/E ratio of 19.89, a PEG ratio of 2.36 and a beta of 0.40.

Johnson & Johnson (NYSE:JNJ) last released its earnings results on Wednesday, July 16th. The company reported $2.77 earnings per share for the quarter, topping the consensus estimate of $2.68 by $0.09. The company had revenue of $23.74 billion for the quarter, compared to the consensus estimate of $22.85 billion. Johnson & Johnson had a net margin of 25.00% and a return on equity of 32.49%. Johnson & Johnson’s revenue was up 5.8% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $2.82 EPS. Johnson & Johnson has set its FY 2025 guidance at 10.800-10.900 EPS. On average, sell-side analysts predict that Johnson & Johnson will post 10.58 EPS for the current fiscal year.

Johnson & Johnson Announces Dividend

The business also recently announced a quarterly dividend, which was paid on Tuesday, September 9th. Shareholders of record on Tuesday, August 26th were given a dividend of $1.30 per share. This represents a $5.20 annualized dividend and a yield of 2.8%. The ex-dividend date of this dividend was Tuesday, August 26th. Johnson & Johnson’s payout ratio is currently 55.61%.

About Johnson & Johnson

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.